Intravenous / Subcutaneous · Amylin analog
Pramlintide
64 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
64
Ongoing
5
Recruiting
1
Completed
44
Sites
271
Countries
5
Endpoints
498
Composite endpoints
21
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Early Phase 1
2
Phase 1
6
Phase 1/2
2
Phase 2
15
Phase 2/3
2
Phase 3
6
Phase 4
10
Not applicable
21
Trials by status
Not yet recruiting
3
Recruiting
1
Active, not recruiting
1
Completed
44
Terminated
4
Withdrawn
5
Unknown
6
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
193
Safety / tolerability / PK
138
Other (unclassified)
54
Weight & body composition
48
Patient-reported / QoL
27
Cardiometabolic biomarkers
24
Other clinical outcomes
14
Top 20 metrics across this asset's endpoints
CGM time-in-rangeGlycemic
28
Postprandial glucoseGlycemic
21
Body weight, absolute change (kg)Weight
16
AUC₀-∞Safety/PK
15
CGM time-above-rangeGlycemic
13
Documented hypoglycemiaSafety/PK
11
Treatment-emergent AEs (any)Safety/PK
10
Severe hypoglycemiaSafety/PK
10
Body weight, % changeWeight
8
HbA1c, changeGlycemic
8
CmaxSafety/PK
7
CGM time-below-rangeGlycemic
7
CGM time-below-rangeSafety/PK
6
Waist circumference, changeWeight
6
Leptin, changeBiomarker
5
Heart rate, changeBiomarker
5
Immunogenicity (ADA)Safety/PK
5
Plasma concentration (steady state)Safety/PK
4
TmaxSafety/PK
3
Fasting glucose, changeGlycemic
3
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
64 of 64
Showing 1-25 of 64 trials